Ashursts takes on financing work for Ark
Ashurst Morris Crisp has acted for biotech company Ark Therapeutics on a £14.4m secondary equity financing.The share issue valued Ark at £62m. Funds were subscribed by financial institutions that included Nomura International, Merlin, BankInvest, Gartmore and Northern Ventures.Ashursts head of life sciences and IT Mark Lubbock led the team for Ashursts, and Ashursts lawyer David […]